Skip to content

Person-checked company records fromPerson-checked records $750See a worked exampleHuman review in progress

Talk to sales

KeptIndex

Amicus Therapeutics, Inc.

Execute multiple launches of Pombiliti and Opfolda

Delivered by the deadline

AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.

Announced
8 Jan 2024
Due
31 Dec 2024
Delivered
by 31 Dec 2024
  • Deadline
  • Met
  • Late
  • Not met
  • Today

What the company said

“Multiple launches expected in 2H 2024”

What we found

Evidence strength A What the grades mean

Amicus Therapeutics successfully executed commercial launches for Pombiliti and Opfolda throughout 2024, with approximately 220 patients treated or scheduled by the end of the year.

  • A
    Amicus Therapeutics, Inc. 8-K filed 2025-01-13 Regulatory filing · published 13 Jan 2025 · retrieved 25 Sep 2026 · kept permanently by the SEC · fingerprint 21e8a6e2a4a7
    “Following a successful first full year of commercial launch, there were ~220 patients treated or scheduled with commercial product as of the end of 2024.” ✓ confirmed on the page
  • A
    Amicus Therapeutics, Inc. 10-K filed 2025-02-19 Regulatory filing · published 19 Feb 2025 · retrieved 25 Sep 2026 · kept permanently by the SEC · fingerprint 288e96a0e1bc
    “Additionally, in 2024, we established reimbursement agreements in multiple E.U. countries, including Spain, Czechia, Italy, Switzerland, and Sweden.” ✓ confirmed on the page

Checked 25 Sep 2026.

Commitment DNA

The structured record of this commitment. Fields the company did not state are left blank rather than guessed.

Event type
Commercial launch
Indicative materiality
Medium rules
Action
Execute
Language
Expected (“expects”, “plans”)

How this entry was checked

  1. Commitment recordedRecorded from the company's filing.
  2. First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
  3. Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.

Confirmed. This outcome counts towards the company's Kept Score. How verification works

Are you Amicus Therapeutics, Inc.? You can publish an official statement next to this entry, free. Add a statement.

Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.

Report an error in this entry Reference: KI-C-2024-C178879-000011 · Corrections policy

The Deadline Report

One email a week: the corporate commitments that came due, which were met, which slipped, and what is due next. Free. Stop any time.

No advertising. We never sell or share your address.